Animal experiments indicate that CTLA4-Ig has the potential to block unwanted immune responses without compromising the ability to fight off other infections. BMS is testing CTLA4 in humans for ...

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

智通财经APP获悉，百时美施贵宝 (BMY.US)宣布，欧盟委员会 (EC)已批准其重磅PD-1抑制剂Opdivo (nivolumab)与CTLA-4靶向抗体Yervoy (ipilimumab)联用，一线治疗不可切除或晚期肝细胞癌 (HCC)成人患者。据悉，美国FDA已接受Opdivo联合Yervoy治疗同一患者群体的补充生物制品许可申请，预计在今年4月21日之前完成审评。

The cytotoxic T lymphocyte–associated antigen 4–Ig prolongs allograft survival in several rodent models and in some instances can lead to tolerance induction, but the exact mechanisms involved have ...

They combined three injections of these nanoparticles with a single injection of the existing drug CTLA4-Ig during the first week after the heart transplantation. This led to long-term acceptance ...

and/or 0.2 mg/dose CTLA-4-Ig (days 0, 2, 4 and 6 after transplantation). Control recipients received 0.25 mg/dose hamster IgG (days 0, 2, 4, 7 and 10). The grafts were observed daily. Rejection ...